HIK.L - Hikma Pharmaceuticals PLC

LSE - LSE Delayed price. Currency in GBp
1,022.50
+15.00 (+1.49%)
At close: 4:35PM GMT
Stock chart is not supported by your current browser
Previous close1,007.50
Open1,001.00
Bid980.00 x 16300
Ask1,195.00 x 34600
Day's range987.60 - 1,036.50
52-week range906.50 - 2,346.00
Volume669,279
Avg. volume1,021,562
Market cap2.46B
Beta0.12
PE ratio (TTM)14.82
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield0.22 (1.44%)
Ex-dividend date2017-08-24
1y target estN/A
  • Reuters2 days ago

    Drugmaker Dermapharm gears up for likely first German IPO of 2018

    German drugmaker Dermapharm is preparing for an initial public offering (IPO), probably stealing a march on much larger Siemens' (SIEGn.DE) healthcare unit Healthineers as the first stock market flotation in Germany this year. Dermapharm, which makes generic drugs, cosmetics, dietary products and medical devices, said on Monday it aimed to raise about 100 million euros ($122 million) in fresh capital to fund growth during an IPO in the first half of 2018. The family owners will also sell shares, and after the IPO 25 percent of the company will be in the hands of public investors, Dermapharm said.

  • Reuters - UK Focus2 days ago

    Drugmaker Dermapharm gears up for likely first German IPO of 2018

    German drugmaker Dermapharm is preparing for an initial public offering (IPO), probably stealing a march on much larger Siemens (BSE: SIEMENS.BO - news) ' healthcare unit Healthineers as the first stock market flotation in Germany this year. Dermapharm, which makes generic drugs, cosmetics, dietary products and medical devices, said on Monday it aimed to raise about 100 million euros ($122 million) in fresh capital to fund growth during an IPO in the first half of 2018. The family owners will also sell shares, and after the IPO 25 percent of the company will be in the hands of public investors, Dermapharm said.

  • Reuters - UK Focus29 days ago

    Hikma wins right to market Roche drug copy in Middle East and North Africa

    Dec (Shanghai: 600875.SS - news) 19 (Reuters) - Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) has won exclusive rights to distribute and market its third biosimilar drug - a copy of Roche's blood cancer treatment Rituxanin - in the Middle East and North African markets, it said on Tuesday. The Jordan-based drugmaker agreed on the licensing deal with Celltrion to market the South Korea-based biopharmaceutical firm's Truxima, a copy of Roche's blockbuster blood cancer medicine, also known as MabThera. Truxima, the first biosimilar cancer drug to hit the European market in February, is used to treat patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis and and microscopic polyangiitis.

  • Reuters2 months ago

    Takeaway app Delivery Hero joins European index in tech-heavy rejig

    German takeaway app Delivery Hero, which listed five months ago, will join the STOXX 600 benchmark index in December as rapidly rising tech stocks dominate its quarterly reshuffle. Delivery Hero's stock is up by around 40 percent from its IPO price, raising its market capitalisation to 6.7 billion euros ($7.9 billion). Along with companies such as Just Eat, which is expected to be promoted to Britain's FTSE 100 index later on Wednesday, Delivery Hero's addition reflects consumer demand for cheap, efficient, on-demand services to order food.

  • 2 turnaround stocks I’d consider buying before 2018
    Fool.co.uk2 months ago

    2 turnaround stocks I’d consider buying before 2018

    Could these two turnaround stocks beat the market in 2018 and beyond?

  • Reuters - UK Focus2 months ago

    European shares suffer worst day since June as earnings underwhelm

    MILAN/LONDON, Nov 9 (Reuters) - European shares fell on Thursday as a series of underwhelming earning updates, including from industrial giant Siemens, prompted investors to take profits out of a market still trading near two-year highs. The pan-European STOXX 600 benchmark index fell 1.1 percent, suffering its biggest daily loss since end-June, while Germany's DAX fell 1.5 percent. The STOXX 600 is up 7.9 percent so far this year following a rally that has been fuelled by a combination of strong economic data, solid earnings and easing political fears.

  • MarketWatch2 months ago

    FTSE 100 closes lower as Burberry sinks the most in five years

    Blue-chip stocks in the U.K. declined Thursday, as house builders fell following soft industry figures and as Burberry shares tumbled the most in more than five years after a disappointing earnings report ...

  • Reuters - UK Focus2 months ago

    Britain's FTSE under pressure as Burberry revamps its strategy

    A drop in luxury group Burberry weighed on the UK's top share index on Thursday, which was stuck below a five-month high as results were the main focus. Britain's blue-chip FTSE 100 index was flat in percentage ...

  • Reuters2 months ago

    Hikma in dispute with FDA over generic Advair, cuts generics sales forecast again

    The dispute between the Jordan-based firm, its partner Vectura (VEC.L) and the U.S FDA delays any eventual approval of the generic version of the drug. Shares of Hikma were down 5.5 percent at market open, while Vectura shares were down about 10 percent.

  • Reuters - UK Focus2 months ago

    Hikma in dispute with FDA over generic Advair, cuts generics sales forecast again

    Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) is in dispute with the Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline (Other OTC: GLAXF - news) 's popular lung drug Advair in the U.S, the drugmaker said on Thursday, when trimming 2017 revenue guidance for its generics business for a third time. The dispute between the Jordan-based firm, its partner Vectura and the U.S FDA delays any eventual approval of the generic version of the drug. Shares (Berlin: DI6.BE - news) of Hikma were down 5.5 percent at market open, while Vectura shares were down about 10 percent.

  • Reuters2 months ago

    Hikma, Vectura in dispute with FDA over generic Advair

    LONDON (Reuters) - Hikma (HIK.L) and its partner Vectura (VEC.L) are in dispute with the Food and Drug Administration over their plans to launch a generic copy of GlaxoSmithKline's (GSK.L) popular lung ...

  • Reuters - UK Focus2 months ago

    Drugmaker Hikma cuts generics sales forecast a third time

    Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) on Thursday lowered 2017 revenue guidance for its generics business for a third time. The Jordan-based firm, which makes and markets branded and non-branded generic and injectable drugs, said it expected revenue of around $600 million and a core operating margin in the low single-digits from its generics business. In August it had lowered its generics revenue guidance by $50 million to about $620 million, having slashed it to $670 million from an initial $800 million last November.

  • Forbes3 months ago

    The U.S. Has A Fentanyl Shortage ... In The Clinic, Not On The Streets

    I fear this means I need to bring my own to my follow-up colonoscopy in November.

  • Reuters - UK Focus5 months ago

    BUZZ-Hikma: More price cuts on visibility issues

    ** Hikma Pharmaceuticals attempts bounce after steep losses since last week's half-year report, up as much as 3.9 pct, but these now almost erased ** Morgan Stanley cuts TP to 1350p from 1600p, Peel Hunt ...

  • Reuters - UK Focus5 months ago

    Drugmaker Hikma's U.S. unit raises medicine prices -Financial Times

    Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) 's U.S. subsidiary has raised the price of a common diarrhea drug by more than 400 percent and is charging more for five other medicines as well, the Financial Times reported on Sunday. West-Ward Pharmaceuticals, the U.S. division of London-listed Hikma, increased the prices at the start of August by between 75 percent and 430 percent, for a mean of 237 percent, according to figures seen by the Financial Times. Among the six drugs, West-Ward is either the only U.S. supplier or one of two manufacturers.

  • Reuters - UK Focus5 months ago

    Fed-fuelled banking stumble cuts short FTSE winning streak

    Banks wilting on the prospect of slower U.S. rate hikes dented Britain's major share index on Thursday, and Kingfisher also weighed after a weaker quarterly sales performance. The FTSE 100 fell 0.6 percent, ...

  • Reuters - UK Focus5 months ago

    Drugmaker Hikma trims sales forecasts, shares fall

    Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) on Thursday said 2017 revenue would be at the lower end of its forecasts, citing increased pricing pressures in the generic drug industry, sending its shares to a more than three-year low. The company had already cut its full-year guidance in May to the range of $2 billion-$2.1 billion at constant currency from $2.2 billion. "Price erosion by the entire generics industry has been significant," Brian Hoffmann, president of the company's U.S. generics business told Reuters.

  • Reuters - UK Focus5 months ago

    Drugmaker Hikma expects 2017 revenue at the lower end of guidance

    Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) said on Thursday it expected 2017 revenue at the lower end of its guidance, after increased competition in the generics business hit prices and volumes. The Jordan-based company, which makes and markets branded and non-branded generic and injectable drugs, said it now expected 2017 revenue to be about $2 billion, at the lower end of its previous forecast of $2 billion-$2.1 billion. In May, London-listed Hikma cut full-year guidance for the first time to the range of $2 billion-$2.1 billion at constant currency, down from $2.2 billion.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes